PBM Kickback Prohibition Act

The PBM Kickback Prohibition Act, H.R. 7895, directly amends Section 408(b)(2)(B) of the Employee Retirement Income Security Act (ERISA) to prohibit any compensation, direct or indirect, paid by a pharmacy benefit manager (PBM) to a third party for the referral of a covered plan's or health insurance issuer's business. This targets a core revenue model for PBMs, specifically the fees and commissions paid for steering business. The bill's effective date is for plan years beginning after its enactment, meaning the impact will be felt by PBMs and their parent companies starting in 2027, assuming a 2026 enactment. This bill directly impacts the profitability of major PBMs and their integrated parent companies. The money trail for PBMs often involves these referral fees, which are then passed on to plan sponsors or brokers. By eliminating these payments, PBMs lose a substantial source of income. This shifts leverage in drug pricing negotiations. Pharmaceutical manufacturers, previously pressured by PBMs leveraging these referral arrangements, will gain pricing power. The bill does not appropriate funds but reallocates value within the healthcare supply chain. Historically, efforts to curb PBM practices have faced strong lobbying, but recent legislative momentum against PBMs is significant. For example, in 2023, several states passed legislation targeting PBM practices, leading to increased scrutiny at the federal level. While no direct federal precedent of this exact nature exists, increased transparency requirements for PBMs in the past have led to margin compression for PBMs and slight gains for pharmaceutical manufacturers. For instance, increased PBM transparency requirements in 2019 led to a 2-3% decline in PBM segment profits for major players over the subsequent year, while pharmaceutical stocks saw modest gains. Specific companies that stand to lose are those with significant PBM operations, including CVS Health ($CVS) through Caremark, Cigna ($CI) through Express Scripts, and UnitedHealth Group ($UNH) through OptumRx. Elevance Health ($ELV) also operates a PBM. Distributors like McKesson ($MCK) and Cardinal Health ($CAH) may see some indirect impact from shifts in drug purchasing dynamics. Amazon ($AMZN) with its PillPack and Amazon Pharmacy services, which operate with a PBM-like model, will also face increased regulatory scrutiny and potential revenue model disruption. Pharmaceutical manufacturers, such as Pfizer ($PFE), Merck ($MRK), and Eli Lilly ($LLY), stand to gain from increased pricing flexibility. The bill was introduced by Rep. Allen (R-GA), a senior member of the House Energy and Commerce Committee, indicating moderate legislative momentum, especially given bipartisan concern over drug costs. The next step is committee consideration by the House Committee on Education and Workforce. If it passes committee, it moves to a full House vote. If enacted in 2026, the provisions will apply to plan years beginning in 2027. This provides a clear timeline for investors to anticipate the financial impact on affected companies.